Navigation Links
Haemonetics Shares Success of Outstanding Fiscal 2009 Performance with Employees
Date:5/4/2009

BRAINTREE, Mass., May 4 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) today reported record revenues and earnings for fiscal 2009 and its eighth consecutive quarter of double digit revenue growth. For the year, Haemonetics reported GAAP net revenues of $598 million, up 16%; operating income of $86 million, up 22%; net income of $59 million, up 14%; and earnings per share of $2.27, up 17%. The Company also announced fiscal 2010 guidance, including continued double digit growth in earnings.

Brian Concannon, President and CEO, announced to Haemonetics employees that the Company accrued in the fourth quarter a special one-time bonus to all employees around the world, with the exception of the senior leaders of the Company, to acknowledge the exceptional performance of fiscal 2009. The Company will spend approximately $2.8 million and the special bonuses will result in a payment of 2% of base salary - just over a week of pay - for nearly every Haemonetics employee worldwide. Neither Brad Nutter, Executive Chairman of the BOD, Brian Concannon, President and CEO, nor the seven other members of the company's Executive Council will receive this special bonus.

Mr. Concannon noted: "Over the last six years Haemonetics has developed a strong reputation for both delivering what we say we will do and paying our shareholders first. Over this period the company has grown from a $330 million medical device company to a $600 million global leader in Blood Management Solutions for our customers. Our 6-year compounded annual growth rates of 10% in revenues, 23% in operating income, and 19% for earnings per share speak to a track record of strong performance. Recognizing the pivotal role that our employees have played in our success, we had the opportunity to grant this special award while still exceeding our business plan and growth goals for fiscal 2009."

In his announcement of the special bonus to employees, Mr. Concannon contrasted the actions taken by Haemonetics with the overall economic environment, saying, "Because of our strong financial discipline and the continued demand for our products and services, we are distinguishing ourselves as a better company at which to work in this increasingly unstable global environment. We have transformed our company and we are working hard to help our customers to transform our industry. I have never been more encouraged and invigorated about our prospects to continue to grow than I am today. We will continue to set high goals for ourselves and exercise strong financial discipline in managing resources."

Haemonetics employs approximately 2,000 people in 17 countries and has its headquarters in Braintree, Massachusetts.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

    Contact:
    Julie Fallon
    Tel. (781) 356-9517
    Alt. Tel. (617) 320-2401


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
9. Haemonetics Chairman and CEO Adopts 10b5-1 Stock Trading Plan
10. Haemonetics Sets Date for First Quarter Fiscal Year 2009 Earnings Release and Conference Call - August 1, 2008
11. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Japanese Zen ... Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on ... mat art pieces, such as Zen Kodo mat. Wanderlust , one of the ...
(Date:9/21/2017)... Boulder, CO (PRWEB) , ... September 21, 2017 ... ... Education Interview of the Month, Lewis and Clark College Emeritus Professor of Education ... Associate Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... voice for people who have kidney disease. The theme “Describe a positive decision ... stories. Entrants needed to meet only one qualification— to have been diagnosed ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced ... Aligner clinical and commercial support services market) has entered into an agreement on ... Australia. , The PGSD is the first private Dental School to launch ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot ... Vaginas.” The goal is to ignite conversation via social media and word-of-mouth regarding ... brand has declared September “Humans with Vaginas” month, releasing a video celebrating the ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: